| Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing GL Melikian, SY Rhee, V Varghese, D Porter, K White, J Taylor, W Towner, ... Journal of Antimicrobial Chemotherapy 69 (1), 12-20, 2014 | 142 | 2014 |
| Detailed transmission network analysis of a large opiate-driven outbreak of HIV infection in the United States EM Campbell, H Jia, A Shankar, D Hanson, W Luo, S Masciotra, ... The Journal of infectious diseases 216 (9), 1053-1062, 2017 | 117 | 2017 |
| Evaluation of transport media and specimen transport conditions for the detection of SARS-CoV-2 by use of real-time reverse transcription-PCR AA Rogers, RE Baumann, GA Borillo, RM Kagan, HJ Batterman, ... Journal of clinical microbiology 58 (8), 10.1128/jcm. 00708-20, 2020 | 102 | 2020 |
| A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients RM Kagan, EP Johnson, M Siaw, P Biswas, DS Chapman, Z Su, JL Platt, ... Public Library of Science 7 (9), e46334, 2012 | 73 | 2012 |
| Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility GL Melikian, SY Rhee, J Taylor, WJ Fessel, D Kaufman, W Towner, ... Antimicrobial agents and chemotherapy 56 (5), 2305-2313, 2012 | 69 | 2012 |
| Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir KG Šašková, M Kožíšek, P Rˇezácová, J Brynda, T Yashina, ... Journal of virology 83 (17), 8810-8818, 2009 | 68 | 2009 |
| Structural analysis of an HIV‐1 protease I47A mutant resistant to the protease inhibitor lopinavir RM Kagan, MD Shenderovich, PNR Heseltine, K Ramnarayan Protein science 14 (7), 1870-1878, 2005 | 64 | 2005 |
| Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery SY Rhee, S Margeridon-Thermet, MH Nguyen, TF Liu, RM Kagan, ... Antiviral research 88 (3), 269-275, 2010 | 63 | 2010 |
| Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region M Kožíšek, KG Šašková, P Řezáčová, J Brynda, ... Journal of virology 82 (12), 5869-5878, 2008 | 56 | 2008 |
| The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a … G Blick, RM Kagan, E Coakley, C Petropoulos, L Maroldo, ... The Journal of infectious diseases 195 (9), 1250-1259, 2007 | 54 | 2007 |
| Structure‐based phenotyping predicts HIV‐1 protease inhibitor resistance MD Shenderovich, RM Kagan, PNR Heseltine, K Ramnarayan Protein science 12 (8), 1706-1718, 2003 | 52 | 2003 |
| Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients EY Kim, MA Winters, RM Kagan, TC Merigan Journal of virology 75 (22), 11227-11233, 2001 | 45 | 2001 |
| Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V M Nijhuis, AMJ Wensing, WFW Bierman, D de Jong, R Kagan, A Fun, ... The Journal of infectious diseases 200 (5), 698-709, 2009 | 42 | 2009 |
| Antiretroviral drug resistance among children and youth in the United States with perinatal HIV RB Van Dyke, K Patel, RM Kagan, B Karalius, S Traite, WA Meyer III, ... Clinical Infectious Diseases 63 (1), 133-137, 2016 | 35 | 2016 |
| Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir KG Šašková, M Kožíšek, M Lepšík, J Brynda, P Řezáčová, J Václavíková, ... Protein Science 17 (9), 1555-1564, 2008 | 35 | 2008 |
| Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase RM Kagan, TS Lee, L Ross, RM Lloyd Jr, MA Lewinski, SJ Potts Antiviral research 75 (3), 210-218, 2007 | 31 | 2007 |
| Trends in HIV-1 drug resistance mutations from a US reference laboratory from 2006 to 2017 RM Kagan, KJ Dunn, GP Snell, RE Nettles, HW Kaufman AIDS research and human retroviruses 35 (8), 698-709, 2019 | 26 | 2019 |
| Methods and compositions for the amplification of mutations in the diagnosis of cystic fibrosis D Huang, F Hantash, R Kagan US Patent App. 10/775,650, 2005 | 26 | 2005 |
| HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization R Kagan, M Winters, T Merigan, P Heseltine AIDS research and human retroviruses 20 (1), 1-9, 2004 | 23 | 2004 |
| Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization RM Kagan, TC Merigan, MA Winters, PNR Heseltine Antiviral therapy 9 (5), 827-828, 2004 | 22 | 2004 |
